UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Teva Pharmaceutical Industries Ltd. |
||||
(Translation of registrants name into English) | ||||
Israel | ||||
(Jurisdiction of incorporation or organization) | ||||
5 Basel Street, P.O. Box 3190 Petach Tikva 49131 Israel |
||||
(Address of principal executive office) |
||||
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [x] Form 20-F [ ] Form 40-F | ||||
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ] | ||||
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ] | ||||
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [ ] Yes [x] No | ||||
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
Teva Pharmaceutical Industries Ltd. | ||
Date: 09/16/2013 | By: |
Eyal Desheh |
Name: | Eyal Desheh | |
Title: | CFO | |
Exhibit No. | Description | |
|
|
|
99.1 | Cancer Research Technology and Teva Pharmaceuticals Form R&D Alliance for Cancer DNA Damage Response Drugs | |
Cancer Research Technology and Teva Pharmaceuticals
Form R&D Alliance for Cancer DNA Damage Response Drugs
Jerusalem and London, September 16, 2013 Cancer Research Technology Ltd. (CRT), Cancer Research UKs technology development arm, and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.
DDR plays a key role in protecting cancer cells from the damaging effect of chemotherapy creating an in-built antidote to the toxic effects of the anti-tumor drug. As the cancer cells that are best able to repair the DNA damage caused by the cancer treatments survive, they replicate, naturally selecting for the mutation with the enhanced repair capability leading to recurrence and resistance to treatment.
Cancer Research UK and CRT, has created a world-class hub of expertise in DDR-related basic, translational, and clinical research that is leading the field; building the understanding that will hopefully enable smarter use of this very interesting approach in the development of new treatment options.
Based on Cancer Research UKs extensive network of leading UK universities, and its five cancer research institutes (Gray Institute, Oxford; Cancer Research UK Cambridge Institute; London Research Institute; Paterson Institute, Manchester; and the Beatson Institute, Glasgow), this hub will provide the foundations for CRTs and Tevas work towards developing novel therapies based on DDR-related targets for the treatment of cancer.
For cancer patients, it is important that we maintain the momentum of progress that has been made in oncology in recent years said Dr. Michael Hayden, President, Teva Global R&D and Chief Scientific Officer. Cancer Research UK, CRT, and their outstanding academic partners, are a driving force in the improved understanding of cancer and its treatment. This research collaboration will build on our understanding of how cells repair DNA damage, help us identify possible points of therapeutic intervention, and lead us onto a pathway toward improve clinical outcomes for cancer patients.
The alliance provides Teva with the opportunity to research and develop selected and differentiated novel treatments targeting DDR processes. With a focus on mechanisms and molecular targets related to the emergence of therapeutic resistance in cancer cells, the partnership also opens up the potential to expand the clinical utility and therapeutic effectiveness of Tevas current portfolio of oncology chemotherapeutic agents. This approach builds on Tevas growing focus on personalized medicine throughout its R&D pipeline, and specifically within its oncology portfolio.
Building on a prior well-established working relationship, the multi-year agreement sets out the provision of new molecular targets, selected by CRT from Cancer Research UKs portfolio of biological research in DDR. These targets will be validated to prove their therapeutic importance before progressing to the early stages of drug discovery in CRTs Discovery Laboratories. CRT and Teva will then jointly undertake chemical lead generation activities. Under the terms of the agreement, CRT will receive research funding and be eligible to receive milestone payments, and royalties on projects advancing through Tevas drug pipeline.
Dr Hamish Ryder, director of drug discovery at CRTs Discovery Laboratories, said: Cancer Research UK scientists are carrying out exciting research in the area of DNA damage repair. Some cancer therapies work by targeting DNA damage response pathways in cancer cells, and finding new ways to block repair in tumors can boost the effectiveness of existing therapies. This exciting alliance with Teva brings together the cutting-edge research funded by Cancer Research UK, CRTs expertise in progressing new drug targets and Tevas drug research and development capabilities in a compelling partnership.
Harpal Kumar, Cancer Research UKs chief executive, said: Our scientists are leading the world in understanding the machinery that causes and subsequently repairs damage to DNA in our cells. We believe this machinery offers many opportunities for new treatments. Cancer Research UK has been at the heart of research that has seen survival from cancer double in the last forty years. By working alongside international partners from industry to discover and develop new targeted cancer drugs we hope to be able to accelerate this progress. This innovative alliance provides a vital new route to turn our research excellence into new drugs to treat cancer patients, hopefully saving more lives, more quickly.
Notes to editors: *The alliance will span the drug discovery process from new target validation - proving a proteins importance as a therapeutic target, though to lead optimization synthesizing compounds for further development as potential drugs.
About Cancer Research Technology
Cancer Research Technology (CRT) is a specialist commercialization and development company, which
aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works
closely with leading international cancer scientists and their institutes to protect intellectual
property arising from their research and to establish links with commercial partners. CRT
facilitates the discovery, development and marketing of new cancer therapeutics, vaccines,
diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the
worlds leading cancer charity dedicated to saving lives through research. Further information
about CRT can be found at www.cancertechnology.com
About Cancer Research UK
Cancer Research UK is the worlds leading cancer charity dedicated to saving lives through
research. The charitys pioneering work into the prevention, diagnosis and treatment of cancer has
helped save millions of lives. Cancer Research UK receives no government funding for its
life-saving research. Every step it makes towards beating cancer relies on every pound donated.
Cancer Research UK has been at the heart of the progress that has already seen survival rates in
the UK double in the last forty years. Cancer Research UK supports research into all aspects of
cancer through the work of over 4,000 scientists, doctors and nurses. Together with its partners
and supporters, Cancer Research UKs vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UKs work or to find out how to support the charity,
please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company,
committed to increasing access to high-quality healthcare by developing, producing and marketing
affordable generic drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the worlds leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about
60 countries. Tevas branded businesses focus on CNS, oncology, pain, respiratory and womens
health therapeutic areas, as well as biologics. Teva currently employs approximately 46,000 people
around the world and reached $20.3 billion in net revenues in 2012.
###